Researchers at Tel Aviv University have developed a new platform using polymeric nanoparticles to deliver drug pairs to ...

RAF 家族共有 ARAF、BRAF 和 CRAF 三个成员，由 RAS 激活的 RAF 将 MEK1/2 磷酸化，并进一步导致 ERK1/2 的磷酸化，最终激活下游负责调节细胞生存、增殖等 ...

A groundbreaking FDA approval has introduced a new treatment option specifically designed for colorectal cancer patients with ...

We played a major role in characterising the BRAF gene and its role in cancer, increasing our understanding of malignant melanoma. Our work on the gene and the structure of the BRAF protein ...

该研究强调了BRAFi是一种潜在的治疗候选药物，可促进贫血的恢复或促进体外红细胞生成。 北京大学生命科学学院李湘盈研究员、西湖大学生命科学 ...

UB-941 (DCBCO0902) is under development for the treatment of malignant melanoma, colon cancer, lung cancer, thyroid cancer, ovarian cancer and other cancer cells harboring BRAF gene mutations. The ...

Plixorafenib is under clinical development by Fore Biotherapeutics and currently in Phase II for Glioma. According to GlobalData, Phase II drugs for Glioma have a 23% phase transition success rate ...

Pfizer (PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies for the ...

Day One Biopharmaceuticals shows promise in pediatric glioma treatment with strong financial health and a promising drug ...

Researchers at Tel Aviv University have developed a new platform using polymeric nanoparticles to deliver drug pairs to ...

Peter Mac scientists have found a way to use the powerful gene editing tool CRISPR to silence cancer-causing gene mutations ...

Craniopharyngioma (CP) is a rare brain tumor that develops in the regions close to the hypothalamus and pituitary gland. The ...